China Metastatic Liver Cancer Clinical Registry Cohort Database

Condition(s) studied

Investigational drug(s) / intervention(s)

Standard of Care for Metastatic Liver Cancer: In this observational patient registry, no specific interventional procedure is assigned by the investigators. Patients included in the database receive standard clinical management and treatments for metastatic liver cancer according to current clinical guidelines and physician's discretion. These procedures may include hepatectomy, ablation, transarterial chemoembolization (TACE), systemic chemotherapy, targeted therapy, or immunotherapy. This registry aims to evaluate the real-world effectiveness and safety of these standard interventions.

Study summary

This study is led by the Department of Hepatobiliary Surgery of the First Affiliated Hospital of the University of Science and Technology of China (USTC), in close collaboration with multiple participating centers nationwide. The primary objective is to establish a standardized, large-scale clinical cohort database specifically for metastatic liver cancer. By collecting comprehensive data on patient demographics, primary tumor characteristics, systemic therapies, and local interventions, this registry aims to elucidate the clinical patterns and prognostic factors of secondary liver malignancies. This database will serve as a robust platform for conducting high-quality real-world studies and advancing evidence-based clinical research in the management of metastatic liver cancer.

Eligibility

Primary outcome measure(s)

• Overall Survival — Up to 10 years
  The time interval from the date of initial diagnosis (or date of enrollment/surgery) to the date of death from any cause.

Trial sites (3)

More Anhui Provincial Hospital trials in China

Other trials for the same condition